NDC 0074-7094
Qulipta
Atogepant
Qulipta is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Abbvie Inc.. The primary component is Atogepant.
| Product ID | 0074-7094_3e500acd-4915-4477-bf46-7284b3591bc2 |
| NDC | 0074-7094 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Qulipta |
| Generic Name | Atogepant |
| Dosage Form | Tablet |
| Route of Administration | ORAL |
| Marketing Start Date | 2021-09-30 |
| Marketing Category | NDA / |
| Application Number | NDA215206 |
| Labeler Name | AbbVie Inc. |
| Substance Name | ATOGEPANT |
| Active Ingredient Strength | 60 mg/1 |
| Pharm Classes | Calcitonin Gene-related Peptide Receptor Antagonist [EPC], Calcitonin Gene-related Peptide Receptor Antagonists [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
Packaging
NDC 0074-7094-04
4 TABLET in 1 BOTTLE (0074-7094-04)
| Marketing Start Date | 2021-10-06 |
| NDC Exclude Flag | N |
| Sample Package? | Y |
Drug Details
NDC Crossover Matching brand name "Qulipta" or generic name "Atogepant"
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0074-7094 | Qulipta | Atogepant |
| 0074-7095 | Qulipta | Atogepant |
| 0074-7096 | Qulipta | Atogepant |
Trademark Results [Qulipta]
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 QULIPTA 90133079 not registered Live/Pending |
ALLERGAN SALES, LLC 2020-08-24 |
© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.